I have seen no indication they are slow rolling the trial enrollment, just the vagaries of establishing trial sites in anticipation of high numbers of severe patients and fighting to have patients leronlimab rather than alternative trial medications.

Awards to management principally in newly created stock, so not money taken from coffers.